4basebio (LON:4BB) Stock Price Up 0.1% - Should You Buy?

4basebio PLC (LON:4BB - Get Free Report)'s stock price traded up 0.1% during trading on Monday . The stock traded as high as GBX 1,170 ($15.14) and last traded at GBX 1,093 ($14.15). 680 shares traded hands during mid-day trading, a decline of 6% from the average session volume of 727 shares. The stock had previously closed at GBX 1,092 ($14.13).

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada reiterated an "outperform" rating and set a GBX 1,600 ($20.71) price objective on shares of 4basebio in a research note on Thursday, March 13th.

4basebio Stock Performance

The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The firm has a 50-day moving average of GBX 1,145.44 and a two-hundred day moving average of GBX 1,243.29. The company has a market capitalization of £147.32 million, a PE ratio of -1,474.36 and a beta of 1.09.

Insider Activity

In other news, insider Amy Walker acquired 1,151 shares of the firm's stock in a transaction on Friday, February 28th. The stock was acquired at an average price of GBX 1,120 ($14.50) per share, for a total transaction of £12,891.20 ($16,685.48). Insiders own 68.44% of the company's stock.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.